Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | PPM1B | O75688 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL390785 | 1.00 | POLB (0.56) | POLBALDH1A1SMN1; SMN2KDM4EAPEX1 | |
| SCHEMBL960068 | 1.00 | POLB (0.56) | POLBALDH1A1SMN1; SMN2KDM4EAPEX1 | |
| SCHEMBL3344598 | 1.00 | POLB (0.56) | POLBALDH1A1SMN1; SMN2KDM4EAPEX1 | |
| SCHEMBL12268155 | 1.00 | POLB (0.56) | POLBALDH1A1SMN1; SMN2KDM4EAPEX1 | |
| SCHEMBL392940 | 1.00 | POLB (0.56) | POLBALDH1A1SMN1; SMN2KDM4EAPEX1 | |
| SCHEMBL1286040 | 1.00 | POLB (0.56) | POLBALDH1A1SMN1; SMN2KDM4EAPEX1 | |
| SCHEMBL15382009 | 1.00 | POLB (0.56) | POLBALDH1A1SMN1; SMN2KDM4EAPEX1 | |
| SCHEMBL390569 | 1.00 | POLB (0.56) | POLBALDH1A1SMN1; SMN2KDM4EAPEX1 | |
| SCHEMBL12268152 | 1.00 | POLB (0.56) | POLBALDH1A1SMN1; SMN2KDM4EAPEX1 | |
| SCHEMBL6737297 | 1.00 | POLB (0.56) | POLBALDH1A1SMN1; SMN2KDM4EAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348363-A1 | COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-11-02 | — | — | US | disclosed |
| US-20230348363-A1 | COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-11-02 | — | — | US | disclosed |
| EP-4259605-A1 | 4-(2-FLUORO-4-METHOXY-5-3-(((1-METHYLCYCLOBUTYL)METHYL)CARBAMOYL)BICYCLO[2.2.1]HEPTAN-2-YL)CARBAMOYL)PHENOXY)-1-METHYLCYCLOHEXANE-1-CARBOXYLIC ACID DERIVATIVES AND SIMILAR COMPOUNDS AS RXFP1 MODULATORS FOR THE TREATMENT OF HEART FAILURE | Astrazeneca AB (SE) | 2023-10-18 | — | — | EP | disclosed |
| US-11667602-B2 | Compounds and their use | ASTRAZENECA AB (SE) | 2023-06-06 | — | — | US | disclosed |
| US-11667602-B2 | Compounds and their use | ASTRAZENECA AB (SE) | 2023-06-06 | — | — | US | disclosed |
| US-11667602-B2 | Compounds and their use | ASTRAZENECA AB (SE) | 2023-06-06 | — | — | US | disclosed |
| US-20230078576-A1 | COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-03-16 | — | — | US | disclosed |
| WO-2022122773-A1 | 4-(2-FLUORO-4-METHOXY-5-3-(((1-METHYLCYCLOBUTYL)METHYL)CARBAMOYL)BICYCLO[2.2.1]HEPTAN-2-YL)CARBAMOYL)PHENOXY)-1-METHYLCYCLOHEXANE-1-CARBOXYLIC ACID DERIVATIVES AND SIMILAR COMPOUNDS AS RXFP1 MODULATORS FOR THE TREATMENT OF HEART FAILURE | ASTRAZENECA AB (SE) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022122773-A1 | 4-(2-FLUORO-4-METHOXY-5-3-(((1-METHYLCYCLOBUTYL)METHYL)CARBAMOYL)BICYCLO[2.2.1]HEPTAN-2-YL)CARBAMOYL)PHENOXY)-1-METHYLCYCLOHEXANE-1-CARBOXYLIC ACID DERIVATIVES AND SIMILAR COMPOUNDS AS RXFP1 MODULATORS FOR THE TREATMENT OF HEART FAILURE | ASTRAZENECA AB (SE) | 2022-06-16 | — | — | WO | disclosed |
| EP-2129224-B1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS INC (US) | 2016-03-30 | — | — | EP | disclosed |
| EP-2346329-B1 | A METHOD OF INHIBITING HEPATITIS C VIRUS BY COMBINATION OF A 5,6-DIHYDRO-1H-PYRIDIN-2-ONE AND ONE OR MORE ADDITIONAL ANTIVIRAL COMPOUNDS | ANADYS PHARMACEUTICALS INC (US) | 2013-08-21 | — | — | EP | disclosed |
| US-20120316156-A1 | [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS FOR LOWERING SERUM URIC ACID | ANADYS PHARMACEUTICALS, INC. (US) | 2012-12-13 | — | — | US | disclosed |
| US-20120302744-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2012-11-29 | — | — | US | disclosed |
| US-8236948-B2 | 5,6-dihydro-1H-pyridin-2-one compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-20120130068-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-8101800-B2 | 5,6-dihydro-1H-pyridin-2-one compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20110229438-A1 | METHOD OF INHIBITING HEPATITUS C VIRUS BY COMBINATION OF A 5,6-DIHYDRO-1H-PYRIDIN-2-ONE AND ONE OR MORE ADDITIONAL ANTIVIRAL COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110166344-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-7939524-B2 | 5,6-dihydro-1H-pyridin-2-one compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-20100034773-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166344-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | DPYD, NQO1, MT-ND5 | POLB 1532/4885ALDH1A1 205/4885SMN1; SMN2 752/4885 |
| US-11667602-B2 | Compounds and their use | RXFP1, RXFP3, RXFP2 | POLB 4827/4885ALDH1A1 1531/4885SMN1; SMN2 2080/4885 |
| US-20100034773-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | HAVCR2, PYGL, HCCS | POLB 1857/4885ALDH1A1 417/4885SMN1; SMN2 1958/4885 |
| US-20120302744-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | DPYD, NQO1, MT-ND5 | POLB 1532/4885ALDH1A1 205/4885SMN1; SMN2 752/4885 |
| US-20110229438-A1 | METHOD OF INHIBITING HEPATITUS C VIRUS BY COMBINATION OF A 5,6-DIHYDRO-1H-PYRIDIN-2-ONE AND ONE OR MORE ADDITIONAL ANTIVIRAL COMPOUNDS | HAVCR2, ZC3HAV1, HCCS | POLB 1525/4885ALDH1A1 1468/4885SMN1; SMN2 1327/4885 |
| US-20120130068-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | DPYD, NQO1, MT-ND5 | POLB 1532/4885ALDH1A1 205/4885SMN1; SMN2 752/4885 |
| US-20230348363-A1 | COMPOUNDS AND THEIR USE | RXFP1, RXFP3, RXFP2 | POLB 4827/4885ALDH1A1 1531/4885SMN1; SMN2 2080/4885 |
| US-20120316156-A1 | [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS FOR LOWERING SERUM URIC ACID | THOP1, XDH, DUOX1 | POLB 3529/4885ALDH1A1 16/4885SMN1; SMN2 2243/4885 |
| US-20230078576-A1 | COMPOUNDS AND THEIR USE | RXFP1, RXFP3, RXFP2 | POLB 4827/4885ALDH1A1 1531/4885SMN1; SMN2 2080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.